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Abstract
In recent years, high frequencies of trimethoprim resistance in urinary tract infections (UTIs) caused by E. coli are have been
reported. Co-resistance to other antimicrobial drugs may play a role in this increase. Therefore, we investigated whether previous
use of other antimicrobial drugs was associated with trimethoprim resistance. We conducted a nested case-control study with
urinary cultures with E. coli from participants of the Rotterdam Study sent in by general practitioners to the regional laboratory
between 1 January 2000 and 1 April 2016. Multivariable logistic regression analysis was performed to study the association
between prior prescriptions of several antimicrobial drug groups and trimethoprim resistance using individual participant data.
Urinary cultures of 1264 individuals with a UTI caused by E. coliwere included. When adjusted for previous other antimicrobial
drug use, a history of > 3 prescriptions of extended-spectrum penicillins (OR 1.68; 95% CI 1.10–2.55) was significantly
associated with trimethoprim resistance of E. coli as was the use of > 3 prescriptions of sulfonamides and trimethoprim (OR
2.22; 95% CI 1.51–3.26). The use of > 3 prescriptions of nitrofuran derivatives was associated with a lower frequency of
trimethoprim resistance (OR 0.60; 95% CI 0.39–0.92), after adjustment for other antimicrobial drug prescriptions. We found
that previous use of extended-spectrum penicillins is associated with trimethoprim resistance. On the contrary, previous
nitrofurantoin use was associated with a lower frequency of trimethoprim resistance. Especially in individuals with recurrent
UTI, co-resistance should be taken into account and susceptibility testing before starting trimethoprim should be considered.
Keywords Trimethoprim resistance . UTIs . E. coli . Antimicrobial drugs . Sulfonamides and trimethoprim . Beta-lactam
antibacterials . Nitrofuran derivatives
Introduction
The increase in antimicrobial resistance is becoming a threat
to the treatment of infections and is directly associated with
the increasing use of antimicrobial drugs [1]. Antimicrobial
drugs are frequently prescribed for urinary tract infections
(UTIs) by general practitioners (GPs). Trimethoprim has often
been prescribed, especially in women with UTIs, and high
frequencies of trimethoprim resistance have been reported
[2]. Urinary cultures from female students from the USA,
positive for E. coli of 2005–2007, were in 29.6% of the cases
resistant to trimethoprim. In the UK, there was 29% resistance
in community UTIs in 2015 and 34% in 2016. In the
Netherlands, the resistance rates for trimethoprim in outpatient
UTIs caused by E. coli increased from 15% in 2000 to 31% in
2010 [3–5]. Use of trimethoprim or other antibiotics was
shown to be an important risk factor [6]. Co-resistance, the
simultaneous resistance of one microbe for two or more anti-
microbial drugs, has been suggested to play a role [4]. For
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example, co-resistance for trimethoprim and amoxicillin
means that use of amoxicillin not only selects for
amoxicillin-resistant but also for trimethoprim-resistant mi-
croorganisms. One of the mechanisms may be that resistance
genes are present on the same plasmid [7].
That co-resistance may be of importance was described in a
recent study in the UK, which showed an association between
higher prescribing rates of extended-spectrum penicillins
(such as amoxicillin) and trimethoprim resistance in
Enterobacteriaceae causing UTIs. Interestingly, an associa-
tion with reduced trimethoprim resistance was shown for
nitrofurantoin and macrolide use [8]. These associations were
at population level and not based on data from individual
patients.
In recent years, trimethoprim has been replaced by
nitrofurantoin in primary care guidelines in the UK and the
Netherlands [4, 5, 9, 10]. Although, trimethoprim resistance
rates substantially decreased with the changing guidelines,
they remain high with 24% resistance in E. coli causing
UTIs in primary care patients in the Netherlands in 2017
[11]. With the unique opportunity of urinary cultures and an-
timicrobial drug prescriptions at the individual level from par-
ticipants of the prospective population-based Rotterdam
Study, we were able to study the effects of prescriptions of
several antimicrobial drug groups on trimethoprim resistance.
Materials and methods
Source population
We conducted a nested case-control study, using urinary cul-
tures obtained from participants of the Rotterdam Study, a
prospective cohort study in older adults in the Ommoord area,
Rotterdam, The Netherlands. The Rotterdam Study was de-
scribed elsewhere [12]. In short, the study started in 1991,
when all inhabitants of Ommoord aged ≥ 55 years were invit-
ed to participate (78% response rate). New cohorts of inhabi-
tants of ≥ 45 years were included later, resulting in 14,926
participants in three cohorts. All participants are invited every
few years for interviews and examinations. The Rotterdam
Study has been approved by the Medical Ethics Committee
of the Erasmus MC and by the Ministry of Health, Welfare
and Sport of the Netherlands, implementing the Wet
Bevolkingsonderzoek: ERGO (Population Studies Act:
Rotterdam Study). All participants provided written informed
consent to participate in the study and to obtain information
from their treating physicians.
Study population
The study population included all participants of the Rotterdam
Study of whom at least one urinary culture was assessed at the
Star-SHL laboratory between January 1, 2000, and April 12,
2016, and which was positive (at least 103 cfu/mL) for E. coli.
The Star-SHL laboratory provides laboratory services for all
GPs in the Rotterdam area, including Ommoord. Midstream
urine was collected and sent to the Star-SHL laboratory accord-
ing to the national guidelines of routine care for GPs in
The Netherlands. These guidelines recommend culturing only
when the patient has clinical signs of a UTI, belongs to a risk
group, suffers from a complicated infection, or has complaints
that did not disappear despite empiric treatment. When multiple
cultures of one individual were sent in, only the first one was
used.
Cases and controls
Cases were individuals with a first urinary culture positive for
E. coli resistant to trimethoprim, whereas controls were indi-
viduals with a first urinary culture positive for E. coli suscep-
tible to trimethoprim in the study period. Before 2010, disk
diffusionwas used to determine the susceptibility of theE. coli
to trimethoprim, whereas after 2010, susceptibility testing was
performed with the VITEK 2 system (VITEK AMS;
bioMerieux Vitek systems, Inc., Hazelwood, MO, USA). In
order to use the same cut-off points, all MIC-values were
interpreted according to the CSLI criteria of before 2010.
Intermediate susceptibility was considered resistant in the
analysis, resulting in a cut-off of > 4 μg/mL. During the period
of disk diffusion susceptibility testing (before 2010), the MIC
breakpoint of trimethoprim has changed from > 8 to > 4 μg/
mL. This may have led to misclassification in this period, but
since only 2 out of 586 isolates had a MIC of 4 μg/mL, it can
safely be assumed that only a very small proportion of the
cultures could have been misclassified. Furthermore, suscep-
tibility of the E. coli for amoxicillin (> 8 μg/mL), amoxicillin-
clavulanic acid (> 8/4 μg/mL), nitrofurantoin (> 32 μg/mL),
and ciprofloxacin (> 4 μg/mL) were determined.
Use of antimicrobial drugs
Computerized records from the pharmacies in the Ommoord
district were used to study medication use of the participants.
The total number of prescriptions of all antimicrobial drugs
between January 1, 1995, and the date of the culture was
determined. All generations of cephalosporins were excluded
because theywere only prescribed to 3 individuals in the study
period. This resulted in the following antimicrobial drug
groups: ATC-codes J01AA (tetracyclines), J01CA (extend-
ed-spectrum penicillins), J01CR (combinations of penicillins
incl. beta-lactamase inhibitors, J01E (sulfonamides and tri-
methoprim), J01F (macrolides and lincosamides), J01MA
(fluoroquinolones), J01XE (nitrofuran derivatives). For each
antimicrobial drug group, exposure per individual was
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categorized according to the number of prescriptions during
the study period: 0, 1, 2 or 3, or > 3 prescriptions.
Furthermore, for all groups, the date of the last prescription
before culture was obtained, after which the time interval be-
tween the antimicrobial drug prescription and urinary culture
was calculated. These time intervals were categorized into use
1–3 months, 3–12 months, and > 12 months before urinary
culture and compared with no use at all during the study pe-
riod. Prescriptions in the month before culture were excluded
from the analysis, since it could not be excluded that these
antimicrobial drugs were prescribed for the UTI that led to
the culture.
Confounders
All analyses were adjusted for sex and age. Serum creatinine
was used to calculate the glomerular filtration rate (GFR),
according to the CKD-EPI equation, using the value closest
to culture [13]. Diabetes mellitus was defined as use of anti-
diabetic medication at the moment of culture. Socioeconomic
status (SES) was scored at baseline according to the UNESCO
criteria. To account for potential bias associated with missing
data, missing values on kidney function (18.4%) and SES
(1.3%) were imputed using multiple imputation (N = 20 im-
putations) in SPSS using the default settings [14]. All avail-
able variables (sex, age, diabetes, the use of the different an-
timicrobial drugs, and the different resistance rates) were used
as predictor variables. Furthermore, follow-up time was cal-
culated as the time between start of the study (1 January 2000)
and urinary culture and used as a potential confounder in the
models.
Analysis and statistical methods
Binary logistic regression was used to study the association
between categorized use of antimicrobial drugs per group as
defined above and trimethoprim resistance (no/yes). For each
antimicrobial drug, we first calculated univariable ORs.
Second, we performed a multivariable analysis for each anti-
microbial drug group in which the OR was adjusted for the
potential confounders age, sex, GFR, SES, diabetes, and
follow-up time (model 1). Third, we performed an overall
analysis of all antimicrobial drug groups in which the ORs
of the antimicrobial drug groups were adjusted for all con-
founders and adjusted for the use of all other studied antimi-
crobial drug groups (model 2). For example, in model 2, the
use of sulfonamides and trimethoprim was adjusted for age,
sex, GFR, SES, diabetes, follow-up time, use of tetracylines,
use of extended-spectrum penicillins, use of combinations of
penicillins, incl. enzyme inhibitors, use of macrolides and
lincosamides, use of fluoroquinolones, and use of
nitrofurantoin during the study period. Furthermore,
Spearman’s correlation coefficients were calculated for the
use of all antimicrobial drug groups.
p < 0.05 was considered to be statistically significant. All sta-
tistical analyses were performed with IBM SPSS Statistics 24.
Results
The study population consisted of 1264 individuals with uri-
nary cultures positive for E. coli of whom 1011 (80.0%) were
women, and with a median age of 75 years. The percentage
resistance to trimethoprim of all E. coli isolates was 31.1%.
Resistance percentages to other antimicrobials in
trimethoprim-resistant E. coli were higher than in
trimethoprim-sensitive E. coli isolates: 86.3% versus 26.5%
were co-resistant to amoxicillin, 26.2% versus 9.2% to
amoxicillin-clavulanic acid, 22.4% versus 4.7% to ciproflox-
acin, and 13.0% versus 4.2% to nitrofurantoin (Table 1). Of all
included individuals, 893 (70.6%) were prescribed at least one
beta-lactam antimicrobial drug during the study period, 745
(58.9%) a sulfonamide and trimethoprim, 466 (39.9%) a flu-
oroquinolone, and 603 (47.7%) nitrofurantoin (Table 1).
Although resistance to all other antimicrobial drugs was
higher in the trimethoprim-resistant E. coli isolates than in
the trimethoprim-sensitive E. coli isolates, the overall use of
antimicrobial drugs was not significantly higher in individuals
with trimethoprim-resistant E. coli isolates. We also studied
the correlations between the use of different antibiotic classes,
which were all negligible to low and none of them was nega-
tive. For example, participants who had received a higher
number of sulphonamides and trimethoprim prescriptions also
had been prescribed a higher number of prescriptions of all
other antimicrobial drug groups, but these correlations were
low (Table 2).
Several antimicrobial drug classes, such as tetracyclines
and fluoroquinolones, seemed to be associated with trimetho-
prim resistance in model 1, but this effect disappeared in mod-
el 2, in which antimicrobial drug use of one class was adjusted
for potential confounding by use of other antimicrobial drug
groups. In model 2, we showed that > 3 prescriptions of
extended-spectrum penicillins were associated with trimetho-
prim resistance (OR 1.68; 95% CI 1.10–2.55), whereas com-
binations of penicillins incl. enzyme inhibitors were not. Also,
> 3 prescriptions of a sulfonamide and trimethoprim were sig-
nificantly associated with trimethoprim resistance (OR 2.22;
95% CI 1.51–3.26). In contrast, > 3 nitrofurantoin prescrip-
tions were significantly associated with a lower frequency of
resistance to trimethoprim (OR 0.60; 95% CI 0.39–0.92)
(Table 3).
The time period since the last prescription of extended-
spectrum penicillins (1–3 months; OR 2.86; 95% CI 1.29–
6.34) was associated with trimethoprim resistance in model
2. This association was not seen for combinations of
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penicillins and enzyme inhibitors. Furthermore, an association
was demonstrated between the use of sulfonamides and tri-
methoprim in the 1–3 months before culture (OR 2.22; 95%
CI 1.27–3.87) and trimethoprim resistance. Although there
was no association with the use of fluoroquinolones 1–
3 months before culture, there was one for 3–12 months
(OR 2.28; 95% CI 1.33–3.19). No association was found be-
tween the use of nitrofurantoin and trimethoprim resistance in
this model 2 using the time intervals (Table 4). However,
when adjusting the timing of the last nitrofurantoin
Table 1 General characteristics of study population
All participants (n = 1264) Participants with UTI with
trimethoprim-resistant
E. coli (n = 393)
Age (years), median (IQR) 75.3 (66.5–83.3) 77.2 (67.6–85.1)
Women, n (%) 1011 (80.0) 323 (82.2)
Kidney function (GFR), median (IQR) 80.3 (69.8–90.1) 79.0 (68.8–89.2)
Diabetes, n (%) 170 (13.4) 58 (14.8)
Trimethoprim resistance, n (%) 393 (31.1) 393 (100)
Amoxicillin resistance, n (%) 570 (45.1) 339 (86.3)
Amoxicillin-clavulanic acid resistance, n (%) 183 (14.5) 103 (26.2)
Ciprofloxacin resistance, n (%) 129 (10.2) 88 (22.4)
Nitrofurantoin resistance, n (%) 88 (7.0) 51 (13.0)
Previous use of sulfonamides and trimethoprim, n (%) 745 (58.9) 264 (67.2)
Previous use of tetracyclines, n (%) 759 (60.0) 241 (61.3)
Previous use of extended-spectrum penicillins, n (%) 690 (54.6) 218 (55.4)
Previous use of combinations of penicillins, incl. enzyme inhibitors, n (%) 602 (47.6) 192 (48.9)
Previous use of macrolides and lincosamides, n (%) 568 (44.9) 184 (46.8)
Previous use of fluoroquinolones, n (%) 466 (39.9) 176 (44.8)
Previous use of nitrofurantoin, n (%) 603 (47.7) 188 (47.8)
General characteristics of the study population. The first column shows the characteristics for all participants, whereas the second column shows the
characteristics only of participants who had a urinary tract infection caused by a trimethoprim-resistant E. coli. Kidney function is the glomerular
filtration rate (GFR), according to the CKD-EPI equation. Furthermore, it shows the number (%) of individuals who had a UTI caused byE. coli resistant
to several antimicrobial drugs and the number (%) of individuals who used at least one antimicrobial drug of different antimicrobial drug groups before
culturing
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Spearman’s rank correlation coefficients for the correlations between the use of different antimicrobial drug groups. The Spearman’s rank correlation
coefficient is used because of skewed distribution of the variables. The strength of the relation can be between − 1 (perfect negative correlation) to 1
(perfect positive correlation) with 0 meaning no correlation present. As a rule of thumb, the size of the strength of the correlation can be interpreted as
follows: 0.9 to 1.0 (− 0.9 to − 1.0) very high correlation, 0.70 to 0.90 (− 0.70 to − 0.90) high correlation, 0.50 to 0.70 (− 0.50 to − 0.70) moderate
correlation, 0.30 to 0.50 (− 0.30 to − 0.50) low correlation, and 0.0 to 0.30 (0.0 to − 0.30) negligible correlation [15]
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Table 3 Associations between
previous use of antimicrobial
drug groups and trimethoprim
resistance
No use 1 prescription 2 or 3 prescriptions > 3 prescriptions
Sulfonamides and trimethoprim
Number of cases (%) 129 (32.8) 80 (20.4) 75 (19.1) 109 (27.7)
Number of controls (%) 390 (44.8) 178 (20.4) 167 (19.2) 136 (15.6)
OR (95% CI) univariable Ref 1.36 (0.98–1.89) 1.36 (0.97–1.90) 2.42 (1.76–3.34)*
OR (95% CI) in model 1 Ref 1.40 (1.00–1.95)* 1.32 (0.94–1.86) 2.28 (1.64–3.17)*
OR (95% CI) in model 2 Ref 1.45 (1.03–2.05)* 1.32 (0.92–1.89) 2.22 (1.51–3.26)*
Tetracyclines
Number of cases (%) 152 (38.7) 84 (21.4) 61 (15.5) 96 (24.4)
Number of controls (%) 353 (40.5) 178 (20.4) 178 (20.4) 162 (18.6)
OR (95% CI) univariable Ref 1.10 (0.79–1.51) 0.80 (0.56–1.13) 1.38 (1.00–1.89)*
OR (95% CI) in model 1 Ref 1.10 (0.79–1.52) 0.84 (0.59–1.19) 1.43 (1.03–1.97)*
OR (95% CI) in model 2 Ref 0.98 (0.69–1.37) 0.72 (0.50–1.05) 1.11 (0.76–1.61)
Extended-spectrum penicillins
Number of cases (%) 175 (44.5) 83 (21.1) 72 (18.3) 63 (16.0)
Number of controls (%) 399 (45.8) 216 (24.8) 164 (18.8) 92 (10.6)
OR (95% CI) univariable Ref 0.88 (0.64–1.19) 1.00 (0.72–1.39) 1.56 (1.08–2.25)*
OR (95% CI) in model 1 Ref 0.93 (0.68–1.27) 1.07 (0.77–1.50) 1.80 (1.23–2.63)*
OR (95% CI) in model 2 Ref 0.93 (0.67–1.28) 1.04 (0.73–1.48) 1.68 (1.10–2.55)*
Combinations of penicillins, incl. enzyme inhibitors
Number of cases (%) 201 (51.1) 84 (21.4) 62 (15.8) 46 (11.7)
Number of controls (%) 461 (52.9) 186 (21.4) 142 (16.3) 82 (9.4)
OR (95% CI) univariable Ref 1.03 (0.76–1.41) 1.00 (0.71–1.41) 1.29 (0.87–1.91)
OR (95% CI) in model 1 Ref 1.06 (0.78–1.45) 1.09 (0.77–1.54) 1.39 (0.92–2.08)
OR (95% CI) in model 2 Ref 0.98 (0.71–1.36) 0.91 (0.63–1.32) 0.98 (0.62–1.55)
Macrolides and lincosamides
Number of cases (%) 209 (53.2) 88 (22.4) 55 (14.0) 41 (10.4)
Number of controls (%) 487 (55.9) 168 (19.3) 132 (15.2) 84 (9.6)
OR (95% CI) univariable Ref 1.22 (0.90–1.66) 0.97 (0.68–1.38) 1.14 (0.76–1.71)
OR (95% CI) in model 1 Ref 1.31 (0.96–1.79) 1.06 (0.74–1.53) 1.27 (0.83–1.91)
OR (95% CI) in model 2 Ref 1.21 (0.87–1.67) 0.90 (0.61–1.32) 0.97 (0.61–1.54)
Fluoroquinolones
Number of cases (%) 217 (55.2) 63 (16.0) 58 (14.8) 55 (14.0)
Number of controls (%) 581 (66.7) 118 (13.5) 95 (10.9) 77 (8.8)
OR (95% CI) univariable Ref 1.43 (1.01–2.02)* 1.64 (1.14–2.35)* 1.91 (1.31–2.80)*
OR (95% CI) in model 1 Ref 1.45 (1.02–2.06)* 1.59 (1.10–2.29)* 1.89 (1.28–2.79)*
OR (95% CI) in model 2 Ref 1.33 (0.92–1.93) 1.43 (0.96–2.13) 1.51 (0.96–2.37)
Nitrofurantoin
Number of cases (%) 205 (52.2) 64 (16.3) 69 (17.6) 55 (14.0)
Number of controls (%) 456 (52.4) 163 (18.7) 130 (14.9) 122 (14.0)
OR (95% CI) univariable Ref 0.87 (0.63–1.22) 1.18 (0.84–1.65) 1.00 (0.70–1.44)
OR (95% CI) in model 1 Ref 0.85 (0.60–1.19) 1.11 (0.79–1.57) 0.99 (0.68–1.44)
OR (95% CI) in model 2 Ref 0.72 (0.51–1.04) 0.86 (0.59–1.27) 0.60 (0.39–0.92)*
Associations between the previously prescribed number (1, 2 or 3, > 3 compared with none) of prescriptions of
antimicrobial agents for individuals with a UTI caused by an E. coli resistant to trimethoprim (cases) compared
with individuals with a UTI caused by an E. coli susceptible to trimethoprim (controls). For each antimicrobial
drug group, it shows the univariable OR; the OR adjusted for the possible confounders sex, age, diabetes, GFR,
SES, and follow-up time (model 1) and the OR adjusted for sex, age, diabetes, GFR, SES, and follow-up time; and
the use of other antimicrobial drug group prescriptions (model 2) *significant with p < 0.05
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Table 4 Associations between the timing of the last prescription of several antimicrobial drug groups and trimethoprim resistance
No use > 12 months 3–12 months 1–3 months
Sulfonamides and trimethoprim
Number of cases (%) 110 (28.0) 101 (25.7) 37 (9.4) 25 (6.4)
Number of controls (%) 377 (43.3) 327 (37.5) 73 (8.4) 39 (4.5)
OR (95% CI) univariable Ref 1.06 (0.78–1.44) 1.74 (1.11–2.72)* 2.20 (1.27–3.79)*
OR (95% CI) in model 1 Ref 1.04 (0.76–1.42) 1.71 (1.08–2.70)* 2.23 (1.28–3.88)*
OR (95% CI) in model 2 Ref 1.00 (0.72–1.39) 1.66 (1.00–2.77)* 2.22 (1.27–3.87)*
OR (95% CI) in model 2 adjusted for number of prescriptions Ref 1.01 (0.72–1.42) 1.55 (0.95–2.52) 2.24 (1.25–4.02)*
Tetracyclines
Number of cases (%) 152 (38.7) 197 (50.1) 25 (6.4) 12 (3.1)
Number of controls (%) 352 (40.4) 437 (50.2) 62 (7.1) 16 (1.8)
OR (95% CI) univariable Ref 1.04 (0.81–1.35) 0.93 (0.57–1.54) 1.74 (0.80–3.76)
OR (95% CI) in model 1 Ref 1.07 (0.82–1.39) 0.92 (0.56–1.52) 1.80 (0.83–3.93)
OR (95% CI) in model 2 Ref 0.90 (0.66–1.21) 0.75 (0.43–1.32) 1.50 (0.64–3.53)
OR (95% CI) in model 2 adjusted for number of prescriptions Ref 0.89 (0.66–1.18) 0.79 (0.48–1.29) 1.52 (0.68–3.39)
Extended-spectrum penicillins
Number of cases (%) 174 (44.3) 166 (42.2) 20 (5.1) 16 (4.1)
Number of controls (%) 393 (45.1) 379 (43.5) 52 (6.0) 15 (1.7)
OR (95% CI) univariable Ref 0.99 (0.77–1.28) 0.87 (0.50–1.50) 2.41 (1.17–4.98)*
OR (95% CI) in model 1 Ref 1.06 (0.81–1.37) 0.97 (0.56–1.69) 2.74 (1.31–5.73)*
OR (95% CI) in model 2 Ref 1.01 (0.75–1.36) 0.95 (0.52–1.74) 2.86 (1.29–6.34)*
OR (95% CI) in model 2 adjusted for number of prescriptions Ref 1.00 (0.76–1.32) 0.87 (0.49–1.56) 2.91 (1.36–6.23)*
Combinations of penicillins, incl. enzyme inhibitors
Number of cases (%) 186 (47.3) 128 (32.6) 31 (7.9) 16 (4.1)
Number of controls (%) 432 (49.6) 277 (31.8) 57 (6.5) 28 (3.2)
OR (95% CI) univariable Ref 1.07 (0.82–1.41) 1.26 (0.79–2.02) 1.33 (0.70–2.51)
OR (95% CI) in model 1 Ref 1.16 (0.88–1.53) 1.24 (0.77–1.99) 1.31 (0.68–2.50)
OR (95% CI) in model 2 Ref 1.11 (0.81–1.52) 0.96 (0.73–1.28) 1.26 (0.62–2.57)
OR (95% CI) in model 2 adjusted for number of prescriptions Ref 1.00 (0.75–1.35) 1.00 (0.62–1.61) 1.07 (0.54–2.12)
Macrolides and lincosamides
Number of cases (%) 208 (52.9) 148 (37.7) 22 (5.6) 9 (2.3)
Number of controls (%) 484 (55.6) 311 (35.7) 50 (5.7) 15 (1.7)
OR (95% CI) univariable Ref 1.11 (0.86–1.43) 1.02 (0.60–1.73) 1.40 (0.60–3.24)
OR (95% CI) in model 1 Ref 1.21 (0.93–1.58) 1.13 (0.66–1.92) 1.43 (0.60–3.37)
OR (95% CI) in model 2 Ref 1.07 (0.80–1.42) 0.90 (0.51–1.60) 1.35 (0.55–3.29)
OR (95% CI) in model 2 adjusted for number of prescriptions Ref
Fluoroquinolones
Number of cases (%) 209 (53.2) 97 (24.7) 33 (8.4) 19 (4.8)
Number of controls (%) 559 (64.2) 193 (22.2) 37 (4.2) 25 (2.9)
OR (95% CI) univariable Ref 1.34 (1.01–1.80)* 2.39 (1.45–3.92)* 2.03 (1.09–3.77)*
OR (95% CI) in model 1 Ref 1.34 (0.99–1.80) 2.50 (1.51–4.15)* 1.86 (0.99–3.48)
OR (95% CI) in model 2 Ref 1.19 (0.84–1.67) 2.02 (1.14–3.65)* 1.66 (0.83–3.34)
OR (95% CI) in model 2 adjusted for number of prescriptions Ref 1.13 (0.81–1.58) 2.28 (1.33–3.19)* 1.59 (0.82–3.07)
Nitrofurantoin
Number of cases (%) 180 (45.8) 91 (23.2) 39 (9.9) 17 (4.3)
Number of controls (%) 386 (44.3) 183 (21.0) 64 (7.3) 57 (6.5)
OR (95% CI) univariable Ref 1.07 (0.78–1.45) 1.31 (0.85–2.02) 0.64 (0.36–1.13)
OR (95% CI) in model 1 Ref 0.99 (0.72–1.37) 1.27 (0.84–1.92) 0.64 (0.36–1.12)
OR (95% CI) in model 2 Ref 0.82 (0.57–1.19) 0.91 (0.57–1.47) 0.54 (0.29–1.01)
OR (95% CI) in model 2 adjusted for number of prescriptions Ref 0.76 (0.54–1.08) 0.97 (0.61–1.53) 0.50 (0.27–0.90)*
Associations between the timing (1–3 months, 3–12 months, > 12 months before culture compared with no use) of the last prescription of antimicrobial
agents for individuals with a UTI caused by an E. coli resistant to trimethoprim (cases) compared with individuals with a UTI caused by an E. coli
susceptible for trimethoprim (controls). For each antimicrobial drug group, it shows the univariable OR, the OR adjusted for the possible confounders
sex, age, diabetes, GFR, SES, and follow-up time (model 1) and the OR adjusted for the sex, age, diabetes, GFR, SES, and follow-up time; and
antimicrobial drug group prescriptions of the other antimicrobial drug groups (model 2) Furthermore, it shows model 2 but adjusted for the number of
prescriptions of the other antimicrobial drug groups instead of the variable that describes the timing of these prescriptions. *significant with p < 0.05
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prescription for the number of prescriptions of the other anti-
microbial drug groups instead of the timing of the last pre-
scription of these groups, nitrofurantoin was associated with
less trimethoprim resistance (1–3 months: OR 0.50; 95% CI
0.27–0.90).
Discussion
In this study, we showed that trimethoprim use and extended-
spectrum penicillins use (such as amoxicillin) were significant-
ly associated with trimethoprim resistance in E. coli causing
UTIs, both for the number of prescriptions (> 3 prescriptions)
as well as for the time interval between the last prescription and
culture (prescription 1–3 months before culture). Additionally,
the use of > 3 prescriptions of nitrofurantoin was associated
with a lower frequency of trimethoprim resistance on a patient
level. Both these results confirm at an individual patient level
the findings from the association study at population level,
mentioned in the “Introduction” section [5].
Nitrofurantoin use, as assessed by prescriptions, was asso-
ciated with a lower frequency of trimethoprim resistance, but
only after adjustment for the number of other antimicrobial
drug prescriptions, including trimethoprim. This suggests that
nitrofurantoin use is inversely associated with trimethoprim
resistance in individuals with a high frequency of antimicro-
bial drug use, possibly due to recurrent UTIs. This result was
not found in the model that studied the timing of the last
prescription, possibly because participants who were pre-
scribed nitrofurantoin shortly before the urine culture were
not or less frequently prescribed another antimicrobial drug
for a UTI episode. Co-resistance to trimethoprim and
nitrofurantoin was low (13%), but higher than overall resis-
tance to nitrofurantoin (7%) and there was a low but positive
correlation between sulfonamides use and trimethoprim or
nitrofurantoin use. Thus, lower trimethoprim resistance might
not to be caused by a decreased frequency of trimethoprim
use, but it may be hypothesized that trimethoprim-resistant
E. coli are eradicated by nitrofurantoin.
Despite the high frequency of use, resistance to
nitrofurantoin remains rather low in contrast to other antimi-
crobial drugs [11]. This might be explained by the observation
that E. colimutants resistant to nitrofurantoin were less able to
multiply, which is a disadvantage compared with
nitrofurantoin-sensitive E. coli [16]. Furthermore, the nfsA
and nfsB, genes, which play a role in nitrofurantoin resistance
are chromosomal and not plasmid-mediated, diminishing the
chance of transfer of these genes to other bacteria. However,
recently, the plasmid-mediated oqxAB has also been shown to
play a role in nitrofurantoin resistance [17]. These character-
istics of nitrofurantoin make it an antimicrobial drug of high
interest in this era of antimicrobial resistance.
The association between sulfonamides and trimethoprim use
and trimethoprim resistance was expected and has been de-
scribed before [6, 18]. We also confirm at the patient level the
association between extended-spectrum penicillins use, such as
amoxicillin, and trimethoprim resistance [8]. Furthermore, the
correlation between sulfonamides and trimethoprim use and
extended-spectrum penicillins use is low. Moreover, since we
adjusted for trimethoprim use in the model, it seems unlikely
that the association between amoxicillin use and trimethoprim
resistance is the result of a combination of a high number of
prescriptions of amoxicillin and trimethoprim. Our data suggest
that co-resistance plays an important role, especially in individ-
uals with high antimicrobial drug use.
The association between fluoroquinolones use and trimeth-
oprim resistance remains unclear. In our analyses, the associ-
ation between fluoroquinolone use and trimethoprim resis-
tance disappeared after adjustment for other antimicrobial
drug groups. In the time interval model, the association with
the last prescription 3–12 months before culture could not be
confirmed in other time periods. The association between
fluoroquinolones use and trimethoprim resistance should
therefore be investigated further. Also, we did not find any
associations with macrolides and lincosamides use, although
Pouwels et al. did find a protective effect of macrolide use on
the resistance to trimethoprim [8]. This is possibly explained
by differences in prescribing patterns between the Netherlands
and UK.
A strength of this study is that we confirmed the results of
an earlier association study with aggregated general practice
data [5] using a nested case-control design with individual
patient data. On the contrary, a limitation of the study is the
fact that we use filled prescription data for antimicrobial drugs
but do not know whether patients were adherent to pharma-
cotherapy. However, since individuals with infections visit
their GP because of complaints and antibiotics are usually
seen by patients as safe and effective, it is reasonable to as-
sume that patients actually have taken the drugs. Furthermore,
our results could be influenced by residual confounding. For
example, it cannot be excluded that there are differences be-
tween GPs in prescribing antimicrobial drugs and in sending
cultures, although there is a national guideline that give rec-
ommendations for diagnostics and treatment of UTIs by GPs
[10]. Finally, the design of the study did not allow us to con-
firm our results by studying the genetic associations of resis-
tance genes in these E. coli isolates.
In conclusion, in individual patients, the use of extended-
spectrum penicillins, such as amoxicillin, is associated with
trimethoprim resistance, possibly via selection by co-resis-
tance. Importantly, use of nitrofurantoin is associated with
lower trimethoprim resistance. This indicates that co-
resistance could be important to take into account when pre-
scribing antimicrobial drugs and that resistance testing is im-
portant in individuals with recurrent UTIs.
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